Published in J Infect Dis on March 01, 2008
Impact of Wolbachia on infection with chikungunya and yellow fever viruses in the mosquito vector Aedes aegypti. PLoS Negl Trop Dis (2012) 1.72
Latest developments and future directions in dengue vaccines. Ther Adv Vaccines (2014) 1.03
Fever versus fever: the role of host and vector susceptibility and interspecific competition in shaping the current and future distributions of the sylvatic cycles of dengue virus and yellow fever virus. Infect Genet Evol (2013) 0.99
Vector competence of Australian mosquitoes for yellow fever virus. Am J Trop Med Hyg (2011) 0.89
Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus. Viruses (2013) 0.87
Dual miRNA targeting restricts host range and attenuates neurovirulence of flaviviruses. PLoS Pathog (2015) 0.84
Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment. Vaccine (2014) 0.84
Stability of yellow fever virus under recombinatory pressure as compared with chikungunya virus. PLoS One (2011) 0.79
Safety concerns with regard to live attenuated flavivirus vaccines. J Infect Dis (2008) 0.79
Recovery of West Nile Virus Envelope Protein Domain III Chimeras with Altered Antigenicity and Mouse Virulence. J Virol (2016) 0.75
Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains. Vaccine (2016) 0.75
Research on dengue during World War II. Am J Trop Med Hyg (1952) 8.76
Resurgent vector-borne diseases as a global health problem. Emerg Infect Dis (1998) 4.20
Live flavivirus vaccines: reasons for caution. Lancet (2004) 3.36
Emerging and resurging vector-borne diseases. Annu Rev Entomol (1999) 3.35
The changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle? Comp Immunol Microbiol Infect Dis (2004) 2.94
Dengue/dengue haemorrhagic fever: history and current status. Novartis Found Symp (2006) 2.90
Genetically engineered resistance to dengue-2 virus transmission in mosquitoes. Science (1996) 2.90
Long-term transmission of defective RNA viruses in humans and Aedes mosquitoes. Science (2006) 2.43
Rarity of adverse effects after 17D yellow-fever vaccination. Lancet (2001) 2.14
Blood-feeding patterns of Aedes aegypti (Diptera: Culicidae) collected in a rural Thai village. J Med Entomol (1993) 2.13
Yellow fever: a disease that has yet to be conquered. Annu Rev Entomol (2007) 1.94
Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology (2002) 1.55
ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol (2004) 1.50
The extent of homologous recombination in members of the genus Flavivirus. J Gen Virol (2003) 1.45
Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction. Am J Trop Med Hyg (2004) 1.26
Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates. J Infect Dis (2008) 1.23
Genetically modified, live attenuated dengue virus type 3 vaccine candidates. Am J Trop Med Hyg (2004) 1.19
Role of the yellow fever virus structural protein genes in viral dissemination from the Aedes aegypti mosquito midgut. J Gen Virol (2006) 1.16
Chemical and gamma-ray mutagenesis of the white gene in Aedes aegypti. Insect Mol Biol (2000) 1.13
A qualitative method for estimating the degree of engorgement of Aedes aegypti adults. J Med Entomol (1972) 1.07
Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14--14--2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes. Am J Trop Med Hyg (2000) 1.05
Construction of yellow fever/St. Louis encephalitis chimeric virus and the use of chimeras as a diagnostic tool. Am J Trop Med Hyg (2004) 1.04
Growth characteristics of ChimeriVax-DEN2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoes. Am J Trop Med Hyg (2002) 1.02
Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from Thailand. Am J Trop Med Hyg (2006) 1.02
Use of the biotin-streptavidin interaction to improve flavivirus detection by immunofluorescence and ELISA tests. J Virol Methods (1985) 0.99
Characterization of an infectious clone of the wild-type yellow fever virus Asibi strain that is able to infect and disseminate in mosquitoes. J Gen Virol (2005) 0.97
Dengue vaccines: problems and prospects. Indian J Med Res (2005) 0.94
Arguments for live flavivirus vaccines. Lancet (2004) 0.91
Manipulation of the yellow fever virus non-structural genes 2A and 4B and the 3'non-coding region to evaluate genetic determinants of viral dissemination from the Aedes aegypti midgut. Am J Trop Med Hyg (2006) 0.88
Arguments for live flavivirus vaccines. Lancet (2004) 0.86
Heterologous resistance to superinfection by louping ill virus persistently infected cell cultures. Arch Virol (1992) 0.79
Technology evaluation: ChimeriVax-DEN, Acambis/Aventis. Curr Opin Mol Ther (2004) 0.79
Transmission of yellow fever virus by aged Aedes aegypti and comments on some other mosquitovirus relationships. Am J Trop Med Hyg (1962) 0.78
Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet (2012) 12.41
A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog (2007) 10.38
West Nile virus: where are we now? Lancet Infect Dis (2004) 3.49
Chikungunya virus adapts to tiger mosquito via evolutionary convergence: a sign of things to come? Virol J (2008) 3.39
Genome-scale phylogenetic analyses of chikungunya virus reveal independent emergences of recent epidemics and various evolutionary rates. J Virol (2010) 3.18
Sequencing of Culex quinquefasciatus establishes a platform for mosquito comparative genomics. Science (2010) 3.18
A critical role for induced IgM in the protection against West Nile virus infection. J Exp Med (2003) 2.89
A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med (2010) 2.62
Limited evolution of West Nile virus has occurred during its southwesterly spread in the United States. Virology (2003) 2.59
Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage 1 West Nile virus strains. J Virol (2005) 2.52
Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat Med (2008) 2.44
Infectious clones of Chikungunya virus (La Réunion isolate) for vector competence studies. Vector Borne Zoonotic Dis (2006) 2.37
Epistatic roles of E2 glycoprotein mutations in adaption of chikungunya virus to Aedes albopictus and Ae. aegypti mosquitoes. PLoS One (2009) 2.22
Chikungunya virus arthritis in adult wild-type mice. J Virol (2010) 2.16
Chikungunya virus emergence is constrained in Asia by lineage-specific adaptive landscapes. Proc Natl Acad Sci U S A (2011) 2.12
From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine (2011) 2.06
The 2002 introduction of West Nile virus into Harris County, Texas, an area historically endemic for St. Louis encephalitis. Am J Trop Med Hyg (2004) 2.02
A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis (2010) 1.96
Yellow fever: a disease that has yet to be conquered. Annu Rev Entomol (2007) 1.94
The enhancement of arbovirus transmission and disease by mosquito saliva is associated with modulation of the host immune response. Trans R Soc Trop Med Hyg (2008) 1.88
An immune-responsive serpin, SRPN6, mediates mosquito defense against malaria parasites. Proc Natl Acad Sci U S A (2005) 1.87
Type I IFN controls chikungunya virus via its action on nonhematopoietic cells. J Exp Med (2010) 1.86
Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines (2008) 1.77
Impact of Wolbachia on infection with chikungunya and yellow fever viruses in the mosquito vector Aedes aegypti. PLoS Negl Trop Dis (2012) 1.72
Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg (2002) 1.70
Potentiation of West Nile encephalitis by mosquito feeding. Viral Immunol (2006) 1.62
Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism. PLoS Pathog (2011) 1.62
Replication cycle of chikungunya: a re-emerging arbovirus. Virology (2009) 1.61
Real-time reverse transcriptase-polymerase chain reaction quantification of West Nile virus transmitted by Culex pipiens quinquefasciatus. Am J Trop Med Hyg (2004) 1.60
Identification of microRNAs expressed in two mosquito vectors, Aedes albopictus and Culex quinquefasciatus. BMC Genomics (2010) 1.59
LARVAL COMPETITION DIFFERENTIALLY AFFECTS ARBOVIRUS INFECTION IN AEDES MOSQUITOES. Ecology (2005) 1.58
Pathogenomics of Culex quinquefasciatus and meta-analysis of infection responses to diverse pathogens. Science (2010) 1.58
trans-Packaged West Nile virus-like particles: infectious properties in vitro and in infected mosquito vectors. J Virol (2004) 1.57
Chikungunya virus nonstructural protein 2 inhibits type I/II interferon-stimulated JAK-STAT signaling. J Virol (2010) 1.55
A single amino acid substitution in the central portion of the West Nile virus NS4B protein confers a highly attenuated phenotype in mice. Virology (2006) 1.54
Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine (2011) 1.53
West Nile virus dissemination and tissue tropisms in orally infected Culex pipiens quinquefasciatus. Vector Borne Zoonotic Dis (2004) 1.51
A prospective cohort study of dengue infection in schoolchildren in Long Xuyen, Viet Nam. Trans R Soc Trop Med Hyg (2010) 1.51
The 2005-2006 Chikungunya epidemic in the Indian Ocean. Vector Borne Zoonotic Dis (2006) 1.50
Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine (2009) 1.48
Development and characterization of a double subgenomic chikungunya virus infectious clone to express heterologous genes in Aedes aegypti mosquitoes. Insect Biochem Mol Biol (2005) 1.45
Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg (2009) 1.45
Aedes aegypti salivary gland extracts modulate anti-viral and TH1/TH2 cytokine responses to sindbis virus infection. Viral Immunol (2004) 1.44
Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. Vaccine (2004) 1.43
Experimental transmission of Mayaro virus by Aedes aegypti. Am J Trop Med Hyg (2011) 1.42
Ultrastructural study of West Nile virus pathogenesis in Culex pipiens quinquefasciatus (Diptera: Culicidae). J Med Entomol (2005) 1.39
Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J (2004) 1.38
Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity. Pediatr Infect Dis J (2011) 1.37
RNA interference-mediated knockdown of a GATA factor reveals a link to anautogeny in the mosquito Aedes aegypti. Proc Natl Acad Sci U S A (2003) 1.36
Differential infectivities of o'nyong-nyong and chikungunya virus isolates in Anopheles gambiae and Aedes aegypti mosquitoes. Am J Trop Med Hyg (2005) 1.30
Year-round West Nile virus activity, Gulf Coast region, Texas and Louisiana. Emerg Infect Dis (2004) 1.28
Epidemiological and clinical observations on patients with dengue in Puerto Rico: results from the first year of enhanced surveillance--June 2005-May 2006. Am J Trop Med Hyg (2008) 1.27
ISG15 is critical in the control of Chikungunya virus infection independent of UbE1L mediated conjugation. PLoS Pathog (2011) 1.26
Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine (2008) 1.24
Infection, dissemination, and transmission of a West Nile virus green fluorescent protein infectious clone by Culex pipiens quinquefasciatus mosquitoes. Vector Borne Zoonotic Dis (2010) 1.23
Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates. J Infect Dis (2008) 1.23
Alterations in the Aedes aegypti transcriptome during infection with West Nile, dengue and yellow fever viruses. PLoS Pathog (2011) 1.22
Nonviremic transmission of West Nile virus. Proc Natl Acad Sci U S A (2005) 1.22
Dengue virus infections in the first 2 years of life and the kinetics of transplacentally transferred dengue neutralizing antibodies in thai children. J Infect Dis (2006) 1.22
Prior exposure to uninfected mosquitoes enhances mortality in naturally-transmitted West Nile virus infection. PLoS One (2007) 1.21
Anopheles gambiae heat shock protein cognate 70B impedes o'nyong-nyong virus replication. BMC Genomics (2007) 1.20
Early clinical features of dengue infection in Puerto Rico. Trans R Soc Trop Med Hyg (2008) 1.19
Salivary gland morphology and virus transmission during long-term cytopathologic West Nile virus infection in Culex mosquitoes. Am J Trop Med Hyg (2007) 1.19
Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine (2005) 1.18
Evaluation of the function of a type I peritrophic matrix as a physical barrier for midgut epithelium invasion by mosquito-borne pathogens in Aedes aegypti. Vector Borne Zoonotic Dis (2008) 1.17
Potential arbovirus emergence and implications for the United Kingdom. Emerg Infect Dis (2006) 1.17
Endocytosis of chikungunya virus into mammalian cells: role of clathrin and early endosomal compartments. PLoS One (2010) 1.16
Role of the yellow fever virus structural protein genes in viral dissemination from the Aedes aegypti mosquito midgut. J Gen Virol (2006) 1.16
Development of Sanofi Pasteur tetravalent dengue vaccine. Hum Vaccin (2010) 1.14
Assessing the potential of a candidate dengue vaccine with mathematical modeling. PLoS Negl Trop Dis (2012) 1.11
Factors shaping the adaptive landscape for arboviruses: implications for the emergence of disease. Future Microbiol (2013) 1.11
Host immune response to mosquito-transmitted chikungunya virus differs from that elicited by needle inoculated virus. PLoS One (2010) 1.09
Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. Am J Trop Med Hyg (2011) 1.08